{'fraction_non_alphanumeric': 0.034974093264248704, 'fraction_numerical': 0.02849740932642487, 'mean_word_length': 5.336065573770492, 'pattern_counts': {'":': 0, '<': 0, '<?xml version=': 0, '>': 0, 'https://': 0, 'lorem ipsum': 0, 'www.': 0, 'xml': 0}, 'pii_count': 0, 'substrings_counts': 0, 'word_list_counts': {'cursed_substrings.json': 0, 'profanity_word_list.json': 0, 'sexual_word_list.json': 0, 'zh_pornsignals.json': 0}}
The allergy‐associated chemokine receptors CCR3 and CCR5 can be inactivated by the modified chemokine NNY‐CCL11

Background:  CC chemokine ligand 11 (CCL11) is the outstanding member of all described CC chemokine receptor 3 (CCR3) ligands and is shown to be selective for this receptor. However, it also activates CCR5 but only in the micromolar range. The in vivo activity of CCL11 is expected to be temporally restricted, as it is degraded by specific proteases such as the dipeptidyl‐peptidase IV (DP4), also termed CD26. Based on the approach to inactivate chemokine receptors in allergic disease models as has been demonstrated for DP4‐resistant n‐nonanoyl (NNY)‐CCL14 and for amino‐oxypentane (AOP)‐CCL5, it is tempting to study similar compounds derived from CCL11.